Complicated Urinary Tract Infection Clinical Trial
Official title:
Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI
This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.
The purpose of this study is to evaluate the blood concentrations and safety of the fixed dose combination of 2 drugs, cefepime with enmetazobactam administered intravenously in participants aged from birth to less than 18-years of age, hospitalised with a complicated urinary tract infection. The treatment duration will be between 3 and 7 days, depending on the time needed for disappearance of signs and symptoms of the infection. The participant will need to be hospitalised at least during the treatment administration period. After the last administration of cefepime and enmetazobactam, there will be the end of treatment visit (EOT), then 2 follow-up visits at 7 days (Test of Cure (TOC)), then 14 days (Late Follow-up (LFU)) after the end of treatment visit. The End of study Visit (EOS) will be conducted via telephone call (or a visit deemed necessary as per the investigator) 28 days after the EOT visit. The participants may be discharged from hospital at the discretion of the investigator after the end of treatment visit but will be required to return to the hospital for the 2 follow-up visits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
| Not yet recruiting |
NCT05060419 -
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
|
Phase 2 | |
| Completed |
NCT03293485 -
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
|
Phase 3 | |
| Recruiting |
NCT04076436 -
Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.
|
||
| Completed |
NCT00690378 -
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
|
Phase 2 | |
| Recruiting |
NCT04876131 -
Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children
|
Phase 4 | |
| Recruiting |
NCT05887908 -
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
|
Phase 3 | |
| Completed |
NCT00921024 -
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
|
Phase 2 | |
| Completed |
NCT03788967 -
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
| Recruiting |
NCT05674032 -
Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis
|
||
| Completed |
NCT01345929 -
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
|
Phase 3 | |
| Completed |
NCT05385536 -
Evaluating UTI Outcomes in at Risk Populations
|
||
| Completed |
NCT01096849 -
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
|
Phase 2 | |
| Not yet recruiting |
NCT03630081 -
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
| Completed |
NCT02024282 -
Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care
|
N/A | |
| Completed |
NCT01644643 -
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
|
Phase 3 | |
| Completed |
NCT03445195 -
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
|
Phase 2 | |
| Completed |
NCT02486627 -
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
|
Phase 3 | |
| Recruiting |
NCT05733104 -
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
|
||
| Recruiting |
NCT04979806 -
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 |